Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

• The prevalence of immune mediated disorders [ Time Frame: Diagnosis of IMD and at 2 years ]

  The prevalence of:

  • Persistent, recurrent or late onset acute GVHD
  • Cutaneous Sclerosis
  • Bronchiolitis Obliterans Syndrome
  • Chronic GVHD
  
  

• Banked blood and urine samples [ Time Frame: At 2 years ]
  Summarized as the percentage of compliance for each center and for the study as a whole
  
  

Allogeneic hematopoietic cell transplantation (HCT) is the only known curative option for many hematologic disorders. After transplantation, many patients develop immune mediated disorders that may be life-threatening such as graft versus host disease (GVHD). The morbidity and mortality associated with HCT-associated immune mediated disorders are major barriers to successful use of transplantation to cure rare hematologic malignancies such as leukemia, lymphoma, multiple myeloma, myelodysplastic/myeloproliferative syndromes amongst other diseases.

With this study, the investigators will investigate the biologic basis for immune mediated disorders after allogeneic HCT, focusing on those developing cutaneous sclerosis, bronchiolitis obliterans syndrome, late acute GVHD and chronic GVHD. The study will enroll 1118 (1018 adults and 100 children) allogeneic HCT patients over a three year period. Subjects will be followed for two years and monitored closely for development of immune mediated disorders. This study will have 5 study visits at day 1, 100, 180, 365, and 730. During these visits, a physical assessment, medication review, blood and urine collection will occur.

If a subject develops an immune mediated disordered, they will be monitored at 3 months, 6 months, 1 year and then annually from the date of diagnosis. During these study visits, a physical assessment, IMD status, and medication review as well as blood and urine collection will occur.